Clinical effects of apatinib mesylate for treatment of multiple brain micrometastases: Two case reports
| Autor: | Jiang-Wei Zhang, Yuan-Yuan Wang, Pei-Min Liu, Yan-Jun Hao, Hai-Rui Duan, Jun-Hui Guo |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.drug_class
Mesylate Cervical adenocarcinoma business.industry Case Report General Medicine Esophageal squamous cell carcinoma Tyrosine-kinase inhibitor Vascular endothelial growth factor 03 medical and health sciences chemistry.chemical_compound 0302 clinical medicine chemistry 030220 oncology & carcinogenesis medicine Cancer research 030211 gastroenterology & hepatology Apatinib business |
| Zdroj: | World Journal of Clinical Cases. 8:1326-1336 |
| ISSN: | 2307-8960 |
| DOI: | 10.12998/wjcc.v8.i7.1326 |
| Popis: | BACKGROUND: Apatinib is a small-molecule multitargeted tyrosine kinase inhibitor. Apatinib has demonstrated encouraging antitumor activities. This study aimed to observe the efficacy and safety of apatinib for the treatment of multiple brain micrometastases. CASE SUMMARY: We report two patients with multiple brain micrometastases after failure of second-line treatment. Both patients had extracerebral metastases. When the patients took 250 mg/d apatinib orally, the intracerebral lesions disappeared. The extracerebral lesions were partially alleviated. Both patients had a progression-free survival of more than 12 mo and were still stable. The safety was good. The main adverse events (AEs) were mild hypertension and proteinuria, which could be controlled. CONCLUSION: Apatinib has clear efficacy and good tolerance in patients with multiple brain micrometastases after failure of second-line treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|